Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
about
CIViC databaseCombined effects of MDM2 SNP309 and TP53 R72P polymorphisms, and soy isoflavones on breast cancer risk among Chinese women in SingaporeThe Pro allele of the p53 codon 72 polymorphism is associated with decreased intratumoral expression of BAX and p21, and increased breast cancer riskCombined effects of single nucleotide polymorphisms TP53 R72P and MDM2 SNP309, and p53 expression on survival of breast cancer patients.TP53 mutations in human cancers: origins, consequences, and clinical useThe Role of p16 and MDM2 Gene Polymorphisms in Prolactinoma: MDM2 Gene Polymorphisms May Be Associated with Tumor ShrinkageA high-frequency regulatory polymorphism in the p53 pathway accelerates tumor development.Germline variation in TP53 regulatory network genes associates with breast cancer survival and treatment outcome.The relative mRNA expression of p53 isoforms in breast cancer is associated with clinical features and outcome.Effect of the MDM2 promoter polymorphisms SNP309T>G and SNP285G>C on the risk of ovarian cancer in BRCA1 mutation carriers.Population distribution and ancestry of the cancer protective MDM2 SNP285 (rs117039649).Association of MDM2 SNP309, age of onset, and gender in cutaneous melanomaIn search of breast cancer culprits: suspecting the suspected and the unsuspectedEvaluating the association between p53 codon 72 Arg>pro polymorphism and risk of ovary cancer: a meta-analysisPrognostic impact of the MDM2SNP309 allele in leukemia and lymphoma.Associations of common variants at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor subtype: findings from the Breast Cancer Association ConsortiumPolymorphisms of TP53 codon 72 with breast carcinoma risk: evidence from 12226 cases and 10782 controlsGermline TP53 mutational spectrum in French Canadians with breast cancer.Association of the TP53 codon 72 polymorphism and breast cancer risk: a meta-analysisA functional genetic variant in fragile-site gene FATS modulates the risk of breast cancer in triparous womenInvolvement of single-nucleotide polymorphisms in predisposition to head and neck cancer in Saudi Arabiap53 codon 72 polymorphism and breast cancer risk: A meta-analysis.The MDM2-p53 pathway revisitedResults based on 124 cases of breast cancer and 97 controls from Taiwan suggest that the single nucleotide polymorphism (SNP309) in the MDM2 gene promoter is associated with earlier onset and increased risk of breast cancer.No evidence for association of the MDM2-309 T/G promoter polymorphism with prostate cancer outcomes.Polymorphisms in p53 and the p53 pathway: roles in cancer susceptibility and response to treatment.The TP53 Arg72Pro and MDM2 309G>T polymorphisms are not associated with breast cancer risk in BRCA1 and BRCA2 mutation carriers.Association between MDM2 rs 2279744 polymorphism and breast cancer susceptibility: a meta-analysis based on 9,788 cases and 11,195 controls.MDM2 SNP309 is associated with endometrial cancer susceptibility: a meta-analysis.The Mdm network and its regulation of p53 activities: a rheostat of cancer risk.Evaluation of the p53 Arg72Pro polymorphism and its association with cancer risk: a HuGE review and meta-analysis.Genetic Modifiers of the p53 Pathway.TP53 Arg 72Pro and MDM2 SNP309 polymorphisms and colorectal cancer risk: a west Algerian population study.Have the roles of two functional polymorphisms in breast cancer, R72P in P53 and MDM2-309 in MDM2, become clearer?Epistatic interaction of Arg72Pro TP53 and -710 C/T VEGFR1 polymorphisms in breast cancer: predisposition and survival.Influence of MDM2 SNP309 and SNP285 status on the risk of cancer in the breast, prostate, lung and colon.Association of p53 Codon 72 Polymorphism with Breast Cancer in a Rwandese Population.MDM2 SNP309 and p53 Arg72Pro in cutaneous melanoma: association between SNP309 GG genotype and tumor Breslow thickness.MDM2 SNP309 polymorphism and breast cancer risk: a meta-analysis.A single-nucleotide polymorphism in the TP53 and MDM-2 gene modifies breast cancer risk in an ethnic Arab population.
P2860
Q27612411-E7F76834-247B-42EF-B865-34C14FB98AA2Q28386766-F9932AE7-B619-4BB0-A413-81CB145A2DCAQ28484331-1A40C29E-2435-413A-A074-B2DD3A2D72BAQ33627208-D338CD8C-5CE4-48D9-9FFF-91109C9DD79CQ33685392-29158EEC-90E3-4269-9353-9687C2BD1550Q33770763-7B87D8FD-0603-4E8F-BF83-D80CB90382E5Q34148472-8DDBD048-FD84-4390-A666-072A0A750697Q34158129-38BBBA66-321B-4E06-BAB6-43864C4D3593Q34391735-BBDF831F-209A-44CD-BCB1-75D318D485A4Q34435034-00DAD43A-A3CF-44C1-8DC3-B0902BCF27A1Q34483516-4264F3A2-D6F7-4C86-84E5-AF54E3A6F729Q34968358-027E0BF8-F86B-4DE6-A331-A1F85F986589Q35015572-20AC3969-2ACC-428D-B2F4-3C1F792D1A4CQ35152940-F06E494F-8509-4762-A53D-2F1739C8083AQ35169579-1C62B48C-CB18-4AAB-9DB2-25ABF3F4AAC6Q35532898-87935958-E5BA-48E8-AA07-68DC381D03A5Q35578056-F7DDBA48-8053-45D1-9B62-B606E9DFBE81Q35618321-761DD65D-930F-4E78-B950-4E5B0B4351DCQ35661603-D5D13EDB-C5EE-4D4B-A94A-09009D15D7D5Q35724445-5C7A2153-4528-465F-974B-F2B10C9E1013Q35752169-BFBE864F-644E-48EF-AD49-BC1F4A7C9CB8Q36900858-9947205F-69CB-4E89-BDF1-DCAAE6114222Q37039474-2BEEF37E-D551-45AA-99B0-BE03DA4FC72CQ37112360-EA5C1713-14F6-4F97-9D28-3BF3F05E15C4Q37195909-1EEC0374-1E16-48F4-8C77-6699E0F92FBDQ37293815-D285E737-B6C6-4171-B078-6279DD53171EQ37401496-B166B55C-5D52-4E89-8713-6186466C6727Q37722658-6C08B689-8E75-428B-96B7-1B6A0DFACC97Q37872630-AC52B739-781A-41D6-92A5-1511A6C28224Q38184520-97EFECAD-EB87-4671-9850-41EB4E156589Q38425166-AE4E7992-612E-4CC2-A506-119209911097Q38796076-F241EAAB-7649-44B8-9AA0-2F6AD544FD06Q38856071-1194C0AB-77EB-4D8F-B6EF-03B2846728C2Q42761882-99D5CD79-147B-466F-9EE5-7A973B284D77Q43541896-D23C13EB-D8E6-44AC-B50B-8405E10C839CQ45859705-2635226D-2704-4F70-B5E8-DF1D42624E86Q46468190-50AF39B3-0EC0-43C4-9D4F-70B17FDFF561Q51560962-37E3E49F-CC9C-4B84-859E-90588DF77BF1Q53086195-D43B7406-7E13-406E-BC57-1F664634A811Q53288178-2A4EBB38-80C0-4273-B5A8-08785F5F9BFD
P2860
Do MDM2 SNP309 and TP53 R72P interact in breast cancer susceptibility? A large pooled series from the breast cancer association consortium.
description
2007 nî lūn-bûn
@nan
2007 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
name
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@ast
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@en
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@nl
type
label
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@ast
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@en
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@nl
prefLabel
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@ast
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@en
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@nl
P2093
P50
P1433
P1476
Do MDM2 SNP309 and TP53 R72P i ...... cancer association consortium.
@en
P2093
Catherine S Healey
Frans B L Hogervorst
Laura J Van't Veer
Linde M Braaf
Rob A E M Tollenaar
Scarlett Reincke
P304
P356
10.1158/0008-5472.CAN-07-0738
P407
P50
P577
2007-10-01T00:00:00Z